Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors | Zendy

Nina Singh | Zendy; Drew J. Winston | Zendy; Raymund R. Razonable | Zendy; G. Marshall Lyon | Zendy; Fernanda P. Silveira | Zendy; Marilyn M. Wagener | Zendy; Terry Stevens-Ayers | Zendy; Bradley Edmison | Zendy; Michael Boeckh | Zendy; Ajit P. Limaye | Zendy

Open Access

Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors

Author(s) -

Nina Singh,

Drew J. Winston,

Raymund R. Razonable,

G. Marshall Lyon,

Fernanda P. Silveira,

Marilyn M. Wagener,

Terry Stevens-Ayers,

Bradley Edmison,

Michael Boeckh,

Ajit P. Limaye

Publication year - 2020

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2020.3138

Subject(s) - medicine , valganciclovir , viremia , asymptomatic , cytomegalovirus , randomized controlled trial , immunology , ganciclovir , neutropenia , foscarnet , gastroenterology , human cytomegalovirus , viral disease , chemotherapy , herpesviridae , virus

Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, high rates of delayed-onset postprophylaxis CMV disease occur. An alternate approach, preemptive therapy (initiation of antiviral therapy for early asymptomatic CMV viremia detected by surveillance testing), has not previously been directly compared with antiviral prophylaxis in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research